December 20, 2023
STELLAPHARM was born to care and protect patient’s health, to help enhancing their lives and living longer. Your health, for today and for future.
The Ho Chi Minh City Department of Health is seeking feedback on the plan to construct a 300-hectare pharmaceutical industrial park during the 2025-30 period, a step to prepare for the city’s export of medical products in the future.
People work inside a medical laboratory in Ho Chi Minh City – Photo: DUYEN PHAN / Tuoi Tre
The pharmaceutical industrial park is included in the draft project on the development of the pharmaceutical industry in Ho Chi Minh City until 2030, with a vision for 2045.
The southern metropolis has several advantages for developing the pharmaceutical industry with many leading universities, high-tech parks, and major factories, according to the health department.
The city also has a large market with 133 hospitals, 1,202 trading businesses, and 6,529 pharmacies.
However, the capacity of pharmaceutical factories in Ho Chi Minh City is still modest as the majority of them can only produce generic drugs.
To meet the high demand for medicine, the health department developed a three-phase road map to build a pharmaceutical industrial park in the city.
They will also identify the types of pharmaceutical products and medical equipment to be manufactured at the park, along with specific criteria for such products.
From 2025 to 2030, the city will carry out the construction of the pharmaceutical industrial park and necessary infrastructure with a scale of about 300 hectares, as well as gradually put it into operation.
From 2030 to 2045, connectivity and open links will be forged between businesses inside and outside the venue.
It is necessary to create mechanisms and policies to bring together domestic and foreign investors so that the pharmaceutical industrial park will be able to produce patent medicines, specialty drugs, and hi-tech generic drugs, the health department said.
The park will also manufacture vaccines, biological products, testing equipment, and hi-tech biomedical products to serve the diagnosis and treatment at domestic health facilities, and to prepare for export to other countries in the region.
Source: Tuoi Tre
Stellapharm is one of leading generics pharmaceutical companies and strong producer of anti-viral drugs in Vietnam. The company established in Vietnam in 2000; and focuses on both prescription drugs and non-prescription especially in cardiovascular diseases, antiviral drugs, anti-diabetics drugs, etc. and our products are now used by millions of patients in more than 50 countries worldwide.
The company is globally recognized for its quality through our facilities have been audited and approved by stringent authority like EMA, PMDA, Taiwan GMP, local WHO and others.
Additional information for this article: Stellapharm J.V. Co., Ltd. – Branch 1
A: 40 Tu Do Avenue, Vietnam – Singapore Industrial Park, An Phu Ward, Thuan An City, Binh Duong Province, Vietnam
T: +84 274 376 7470 | F: +84 274 376 7469 | E: firstname.lastname@example.org | W: www.stellapharm.com
The Circular is an important legal basis for attracting investment activities and transferring technology for drug production, especially original brand name drugs, patented drugs, specialized drugs, special treatments, and prescription drugs. generic drugs in the form of high-tech dosage forms, vaccines, reference biological products, and similar biological products according to the orientations in the
Major drugmakers are using artificial intelligence to find patients for clinical trials quickly, or to reduce the number of people needed to test medicines, both accelerating drug development and potentially saving millions of dollars.Human studies are the most expensive and time-consuming part of drug development as it can take years to recruit patients and trial
Vietnam has set a target of becoming a high-value pharmaceutical production center in the region under its strategy for the development of the pharmaceutical sector by 2030 with a vision to 2045. Under the strategy, which was approved by Deputy Prime Minister Tran Hong Ha on October 9, Vietnam will strive to develop its pharmaceutical
Vietnam is focusing on improving research capacity and application of new drug production technology, promoting clinical pharmacy development and strengthening supervision of safe and reasonable drug use. Vietnam is focusing on improving research capacity and application of new drug production technology, promoting clinical pharmacy development and strengthening supervision of safe and reasonable drug use, aiming